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The Eph receptor tyrosine kinases and their membrane-tethered ephrin ligands provide critical guidance cues at points of
cell-to-cell contact. It has recently been reported that the ephrin-B2 ligand is a molecular marker for the arterial
endothelium at the earliest stages of embryonic angiogenesis, while its receptor EphB4 reciprocally marks the venous
endothelium. These findings suggested that ephrin-B2 and EphB4 are involved in establishing arterial versus venous identity
and perhaps in anastamosing arterial and venous vessels at their junctions. By using a genetically engineered mouse in
which the lacZ coding region substitutes and reports for the ephrin-B2 coding region, we demonstrate that ephrin-B2
expression continues to selectively mark arteries during later embryonic development as well as in the adult. However, as
development proceeds, we find that ephrin-B2 expression progressively extends from the arterial endothelium to
surrounding smooth muscle cells and to pericytes, suggesting that ephrin-B2 may play an important role during formation
of the arterial muscle wall. Furthermore, although ephrin-B2 expression patterns vary in different vascular beds, it can
extend into capillaries about midway between terminal arterioles and postcapillary venules, challenging the classical
conception that capillaries have neither arterial nor venous identity. In adult settings of angiogenesis, as in tumors or in the
female reproductive system, the endothelium of a subset of new vessels strongly expresses ephrin-B2, once again contrary
to earlier views that such new vessels lack arterial/venous characteristics and derive from postcapillary venules. While
earlier studies had focused on a role for ephrin-B2 during the earliest embryonic stages of arterial/venous determination, our
current findings using ephrin-B2 as an arterial marker in the adult challenge prevailing views of the arterial/venous identity
of quiescent as well as remodeling adult microvessels and also highlight a possible role for ephrin-B2 in the formation of the
arterial muscle wall. © 2001 Academic Press
Key Words: artery; vein; capillary; Eph; ephrin; receptor tyrosine kinase; pericyte; angiogenesis; vasculogenesis; PECAM;
CD31; alpha-smooth muscle actin.e
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The Eph receptor tyrosine kinases comprise the largest
known family of growth factor receptors and utilize the
similarly numerous ephrins as their ligands (Flanagan and
Vanderhaeghen, 1998; Gale and Yancopoulos, 1997). The
1 To whom correspondence should be addressed. Fax: (914) 347-
e5045. E-mail: nick.gale@regpha.com.
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All rights of reproduction in any form reserved.phrins are unlike ligands for other receptor tyrosine ki-
ases in that they must be membrane-tethered in order to
ctivate their Eph receptors (Davis et al., 1994; Gale and
ancopoulos, 1997). The obligate membrane-attachment of
he ephrins provided the first clue that they might act
recisely at points of cell-to-cell contact. Based on their
eans of tethering to the cell membrane, the ephrins can be
ubdivided into two subclasses. The five members of the
phrin-A subclass (ephrin-A1 to -A5) are attached to the
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152 Gale et al.outer leaflet of the plasma membrane via a glycosylphos-
phatidylinositol (GPI) anchor, whereas the three members
of the ephrin-B subclass (ephrin-B1 to -B3) have a trans-
membrane region and highly conserved cytoplasmic do-
mains. Ephrin-B ligands primarily interact with the B sub-
set of Eph receptors, consisting of at least six members
(Flanagan and Vanderhaeghen, 1998; Gale and Yancopoulos,
1997, 1999). Interactions between ephrin-B ligands and
EphB receptors apparently activate bidirectional signaling,
in that the cytoplasmic domains of not only the engaged
receptor but also of the interacting ligand become phos-
phorylated on tyrosine residues (Bruckner et al., 1997;
Holland et al., 1996).
The ephrins and Ephs were initially studied for their
ctions in the nervous system, where they seem to play
mportant roles in axonal guidance and in neuronal pattern-
ng (Flanagan and Vanderhaeghen, 1998; Gale and Yanco-
oulos, 1997). More recent studies have begun to focus on
oles of these molecules outside of the nervous system.
phrin-B2 and its cognate EphB4 receptor have recently
ttracted attention in the field of cardiovascular develop-
ent, based on the vascular defects observed in embryonic
ice bearing null mutations in the genes for this ligand and
eceptor pair (Adams et al., 1999; Gerety et al., 1999; Wang
t al., 1998). Normal vascular development initiates with a
asculogenic phase that involves formation of a primitive
ascular scaffold, followed by angiogenic stages during
hich this early vasculature undergoes remodeling and
aturation (Risau, 1997). Mouse embryos lacking
phrin-B2 and EphB4 suffer fatal defects in early angiogenic
emodeling (Adams et al., 1999; Gerety et al., 1999; Wang et
al., 1998). Moreover, ephrin-B2 and EphB4 display a remark-
ably reciprocal pattern of distribution within the develop-
ing vasculature, that is, ephrin-B2 marks the endothelium
of primordial arterial vessels while EphB4 marks the endo-
thelium of primordial venous vessels (Adams et al., 1999;
Gerety et al., 1999; Wang et al., 1998). These distributions
suggested that ephrin-B2 and EphB4 are involved develop-
mentally in establishing arterial versus venous identity,
perhaps in joining arterioles to venules, and that defects in
these processes might account for the early lethality ob-
served in mouse embryos lacking these proteins (Adams et
al., 1999; Gale and Yancopoulos, 1999; Gerety et al., 1999;
Wang et al., 1998; Yancopoulos et al., 1998).
Despite the remarkably reciprocal distributions of
ephrin-B2 and EphB4 during very early vascular develop-
ment, little is known about the distribution or functions of
these proteins as vascular development proceeds, in the
quiescent adult vasculature, or when angiogenesis is reini-
tiated in the adult such as in tumors or in tissue remodel-
ing. To explore these issues, we exploited a genetically
engineered mouse in which the LacZ coding region was
used to substitute and report for the ephrin-B2 coding
region. We note that ephrin-B2 expression continues to
selectively mark arteries during later embryonic develop-
ment as well as in the adult. However, as development
Copyright © 2001 by Academic Press. All rightroceeds, we find that ephrin-B2 expression progressively
xtends from the arterial endothelium to the surrounding
rterial smooth muscle and to pericytes; the precise point
long the microvasculature at which ephrin-B2 expression
ecomes undetectable varies in different circulatory beds,
ut in some cases can mark capillaries to the midway point
etween terminal arterioles and postcapillary venules.
hese findings challenge the classical concept that capillar-
es have neither arterial nor venous identity as had previ-
usly been questioned using other approaches (Lojda, 1979;
razkova et al., 1986). In adult settings of angiogenesis, as
n tumors or in the female reproductive system, the endo-
helium of a subset of new vessels strongly expresses
phrin-B2, once again contrary to earlier views that such
ew vessels lack arterial/venous characteristics and derive
rom postcapillary venules (Gimbrone et al., 1974; Grunt et
l., 1986a,1986b). While earlier studies had focused on a
ole for ephrin-B2 during the earliest embryonic stages of
rterial/venous determination, our current findings suggest
hat ephrin-B2 continues to play an important role during
he development of arteries, perhaps by regulating
ndothelial–smooth-muscle interactions involved in the
ormation of the muscle wall. Furthermore, our current
ndings using ephrin-B2 as an arterial marker in the adult
hallenge prevailing views of the arterial/venous identity of
uiescent as well as remodeling adult microvessels and also
ighlight a possible role for ephrin-B2 in the formation of
he muscle wall of vessels.
MATERIALS AND METHODS
Targeting Vector Construction and ES Cell
Manipulations
The 59 and 39 ephrin-B2 gene fragments used in the construction
of the targeting vector were isolated from a 129SV mouse genomic
library in the lambda FixII vector (Stratagene, La Jolla, CA). The 59
region of homology incorporated in the targeting construct con-
sisted of a 6.7-Kb Eag1 restriction fragment derived from an
ephrin-B2 genomic clone (the 59 Eag1/Not1 site was contributed by
the lambda FixII phage from which this fragment was obtained),
which terminated at its 39 end 51 nucleotides upstream of the
ephrin-B2 start codon. This fragment was cloned into a Not1 site
upstream of a promoterless LacZ cDNA in the vector pKOVpLacZ,
which comprises the LacZ gene followed by the phosphoglycerate
kinase promoter driven neomycin resistance (Neo) gene (PGK-Neo)
(Suri et al., 1996). A 39 region of homology consisting of a 2-Kb
Eag1–Xba1 fragment, which terminates at its 59 end approximately
100 nucleotides downstream of intron1/exon1 boundary, was sub-
cloned into a HindIII site of pKOVpLacZ between the PGK-Neo and
HSV-tk expression units using HindIII linkers (Suri et al., 1996). In
this targeting scheme 281 nucleotides of the ephrin-B2 gene,
including the transcriptional start site and signal sequence, were
deleted and replaced by the LacZ and Neo genes. Gene targeting in
ES cells and mice derived from them were confirmed by Southern
blotting. Faithful expression of the LacZ gene, driven by the
endogenous ephrin-B2 gene promoter, was confirmed by immuno-
histochemical and in situ hybridization analysis. The lacZ-labeled
Ephrin-B2 gene was bred into C57BL/6 and FVB/N strains of mice.
s of reproduction in any form reserved.
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153Ephrin-B2 Labels Arteries of Embryos and AdultsTumor Models
Lewis Lung carcinoma cells (5 3 105) were injected under the
dorsal skin of syngeneic adult ephrin-B2 heterozygous mice. Ten to
14 days postimplantation a palpable tumor could be visualized
under the skin at the injection site. In some cases subcutaneously
injected tumor cells formed tumors within the thigh or flank
muscle adjacent to the injection site, allowing the evaluation of
both subcutaneous and intramuscular tumors. All experimental
procedures were approved by the Committees on Animal Research
of UCSF and Regeneron Pharmaceuticals.
Imaging the Vasculature
Generally the vasculature was made visible by in vivo labeling
with biotin-labeled Lycopersicon esculentum lectin (100 mg in 100
ml 0.9% NaCl, Vector Laboratories, Burlingame, CA) as described.
(Thurston et al., 1996). In some cases, the vasculature was made
visible by postmortem perfusion of a solution of 1 mg/ml FITC-
labeled dextran (Sigma) in PBS. Tissues were prepared as whole-
mount specimens (aorta, vena cava, femoral artery and vein,
trachea, cremaster, and external oblique muscles) or were infil-
trated overnight with 30% sucrose, frozen in Tissue-Tek OCT
compound (Sakura Finetek, Torrance, CA), and sectioned with a
cryostat at a thickness of 100 mm. Biotin-labeled lectin was
isualized as described (Thurston et al., 1996). LacZ activity was
etected histochemically by X-Gal staining as described previously
Suri et al., 1996).
For immunofluorescent detection, tissues were fixed by vascular
erfusion of 2% paraformaldehyde and washed with several rinses
f PBS. Sections were incubated in 5% normal goat serum at room
emperature for 1 h followed by 12–15 h in primary antibody
olution in PBS/Triton. PECAM (CD31) immunoreactivity was
etected by a rat anti-mouse CD31 monoclonal antibody (Pharm-
ngen, San Diego, CA) diluted 1:500, followed by 4 h in Cy3-labeled
oat secondary anti-rat IgG antibody (Jackson ImmunoResearch,
est Grove, PA) diluted 1:200 in PBS/Triton. Ephrin-B2 LacZ
ctivity was detected by a rabbit polyclonal antibody (5 Prime3 3
Prime, Boulder, CO) diluted 1:1000, followed by 4 h in FITC-
labeled goat secondary anti-rabbit IgG antibody. Alpha smooth-
muscle actin was detected with a Cy3-labeled mouse monoclonal
antibody (Sigma) diluted 1:1000. For DAB immunohistochemistry
antibodies to PECAM (see above) and aSMA/HRP (Dako Corp.,
arpinteria, CA) were detected with anti-rat biotin-labeled second-
ry antibodies (Vector Labs, Burlingame, CA) at a 1:500 dilution.
RESULTS
Ephrin-B2 Continues to Specifically Mark Arteries
in the Adult, but Is Unexpectedly Expressed by the
Smooth Muscle of These Vessels
By examining the distribution of the LacZ reporter in
whole mounts and in histological sections prepared from
numerous adult organs, we find that ephrin-B2 expression
continues to specifically mark arterial as opposed to venous
vessels in the adult. In our study of adult mice, we first
examined the largest vessels, including the aorta (Fig. 1A),
the superior and inferior vena cavae (Fig. 1A), the pulmo-
nary vessels, and the femoral vessels (Fig. 1B). In general,
ephrin-B2 expression specifically marked large arteries but b
Copyright © 2001 by Academic Press. All rightot large veins. However, unlike the situation described in
arly embryos, ephrin-B2 expression was not limited to the
ndothelial lining of the large arteries, but was prominently
bserved in the smooth-muscle cells circumferentially en-
ircling these large arteries (e.g., Figs. 1C–1E). Although the
ndothelium and smooth-muscle cells comprising the walls
f large veins did not generally express ephrin-B2, there was
otable expression within the arterioles and capillaries of
he vasa vasorum which nourish the walls of these large
essels (Fig. 1A). The femoral vein provided a rare exception
o the general rule that ephrin-B2 was not expressed in the
alls of large veins; ephrin-B2 was expressed by circumfer-
ntial smooth-muscle cells in this particular vein (Fig. 1B).
We next evaluated ephrin-B2 expression in smaller adult
essels. In these cases, some of the vessels are difficult to
isualize without specific markers due to their fragility and
ransparency. Therefore, we used FITC–dextran or lectin
erfusion of the vasculature, which allowed for the visual-
zation of the entire vasculature in whole-mount prepara-
ions. FITC–dextran perfusion of the vasculature of the
xternal oblique muscle of the abdomen allowed for the
lear demonstration that only arteries and arterioles ex-
ressed ephrin-B2, while the corresponding veins were
egative (Figs. 1F and 1G). Biotinylated lectin perfusion,
hich reveals even finer vascular networks with high
esolution, showed that ephrin-B2 expression extended into
he microvasculature, marking capillaries to approximately
he midway point between arterial and venous vessels,
uggesting that capillaries exhibit arterial/venous charac-
eristics. Thus, as seen within the cremaster muscle and in
he trachea, smaller and smaller arterial branches remain
ositive until staining is lost within the intervening capil-
aries, midway between the arterioles and the postcapillary
enules (Figs. 1H and 1I); within this intervening microvas-
ulature, both endothelial cells and pericytes can express
phrin-B2.
Because different adult tissues have many differences in
he morphology and in the properties of their vascular beds,
e next compared the distribution of ephrin-B2 in a large
umber of adult organs. Despite important differences in
he details of ephrin-B2 expression in different vascular
eds, a consistent finding was that ephrin-B2 was expressed
rimarily in the arterial side of all of these vasculatures, and
ften prominently by the smooth muscle of these vessels.
n the brain large arteries were clearly ephrin-B2 positive
hile veins were ephrin-B2 negative, but it was hard to
etect ephrin-B2 expression in small arterioles and capillar-
es (Figs. 2A and 2B); in brain, numerous neurons also
xpress ephrin-B2. In striking contrast to brain, cardiac and
keletal muscle express ephrin-B2 at high levels in their
mall arterioles and even in their capillaries (Figs. 2C and
D); in these tissues, ephrin-B2 expression was clearly
oted on smooth muscle in arteries and arterioles and in
ericytes in capillaries. Ephrin-B2 revealed yet another
attern within the distinct vasculature of the spleen, in
hich the arterial circulation drains into sinusoids before
eing collected by the venous circulation. In the spleen, the
s of reproduction in any form reserved.
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154 Gale et al.arterial circulation lies mainly within the white pulp while
the venous circulation lies within the splenic red pulp, and
ephrin-B2 expression is clearly limited to the central arter-
ies, arterioles, and capillaries of the white pulp, terminating
FIG. 1. Ephrin-B2 continues to specifically mark arteries in the
vessels. (A–I) From ephrin-B2/LacZ mice. (A) Whole-mount view
activity. The aorta expresses ephrin-B2, while the vena cava does no
and vein. Ephrin-B2 expressing smooth muscle cells within the fem
ephrin-B2/LacZ expression compared to SMA immunohistochemi
chemistry [revealing the endothelial cell lining (as indicated)]. Arr
lumen of the aorta. (F–G) Whole-mount ephrin-B2/LacZ of external
in arterial structures. Arteries (A) and veins (V) are indicated. (H–
showing ephrin-B2/LacZ expression within complete microvasculaabruptly at the marginal zone between white and red pulp h
Copyright © 2001 by Academic Press. All righthere venous sinuses originate (Fig. 2E); high-
agnification views of the splenic arterioles indicate that
phrin-B2 is being expressed by the endothelium of these
essels (Fig. 2F). In the liver ephrin-B2 is expressed by the
t, but is unexpectedly expressed by the smooth muscle of these
aorta and vena cava from ephrin-B2/LacZ mice reacted for bGal
cept in the vasa vasorum. (B) Whole-mount views of femoral artery
vein are indicated by arrowheads. (C–E) Sections of aorta showing
(revealing smooth-muscle cell layers) and PECAM immunohisto-
ead in (D) indicates ephrin-B2-positive endothelial cell lining the
ue muscles compared to FITC dextran perfusion showing lacZ only
tin-perfused whole-mount preparations of cremaster and trachea
cuits. Arteries (A) and veins (V) and capillaries (C) are indicated.adul
s of
t, ex
oral
stry
owh
obliq
I) Lecepatic artery and not the central vein, with weak and
s of reproduction in any form reserved.
155Ephrin-B2 Labels Arteries of Embryos and AdultsFIG. 2. Variations in extent and limit of ephrin-B2 expression in various vascular beds revealed by comparison of ephrin-B2/LacZ expression
and lectin labeling of vasculature. (A–B) Low- and high-magnification views of thick sections of brain (cerebral hemisphere). Neurons express
strong LacZ activity large arteries express ephrin-B2, but brain capillary endothelial cells (arrows) and pericytes appear negative. (C–D) Striated
muscle of heart (C) and skeletal muscle (D) has strong LacZ activity around capillaries (arrows), possibly located in pericytes. (E, F) Low- and
high-magnification views of spleen. Strong LacZ activity is observed in smooth-muscle cells of the central artery in splenic white pulp
(arrowheads in E) and in endothelial cells of terminal arterioles (arrowheads in F). (G–H) Low- and high-magnification views of kidney. Strong
LacZ activity is observed in the interlobular artery, glomeruli (Gl), afferent and efferent arterioles (Af and Ef in H), and proximal kidney tubules.
Ephrin-B2 is expressed in both arterial smooth-muscle cells and endothelial cells (arrowheads in inset in G). (I–J) Low- and high-magnification
views of thick sections of lung. Strong LacZ staining is observed in the endothelial cells of the pulmonary arteries (arrowheads in I and J).
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156 Gale et al.scattered expression by cells within liver sinusoids (not
shown). The kidney provides another unique configuration
of vessels, with the initial arterial vessels eventually
branching into afferent arterioles that then each further
branch into a tuft of glomerular capillaries, only to then
rejoin to form an efferent arteriole exiting the glomerulus;
efferent arterioles then give rise to a second network of
capillaries, the peritubular capillaries, which then coalesce
into venous vessels. In the complex vasculature of the
kidney, ephrin-B2 once again specifically marks the various
arterial vessels. In afferent arteriolar walls, it appears as if
ephrin-B2 is highly expressed by both arterial endothelium
and smooth muscle (inset, Fig. 2G), while it is difficult to
resolve the cell types that express ephrin-B2 within the
glomerulus. Ephrin-B2 expression decreases in efferent ar-
terioles and is undetectable in peritubular capillaries and
the downstream venous circulation (Figs. 2G and 2H).
Finally, the lung conforms to the pattern of arterial-specific
expression of ephrin-B2. In the lungs, ephrin-B2 expression
is clearly seen in endothelial cells of pulmonary arteries and
their primary and secondary branches, with only weak
expression by the smooth muscle cells of the pulmonary
arteries (Figs. 2I and 2J); pulmonary venules and veins do
not express ephrin-B2 (not shown).
During Development, Ephrin-B2 Progressively
Extends from Specifically Marking Arterial
Endothelium to Also Marking Arterial
Smooth Muscle
Our finding that ephrin-B2 is highly expressed by vascu-
lar smooth-muscle cells in adult arteries was rather unex-
pected and differed from the endothelial-specific expression
of ephrin-B2 described in early embryonic arteries (Adams
et al., 1999; Wang et al., 1998). Thus, we sought to deter-
ine the progression of ephrin-B2 expression during embry-
nic development. Staining for the LacZ reporter of
phrin-B2 expression was compared with staining for an
ndothelial marker (PECAM) as well as a smooth-muscle
arker (smooth-muscle actin, SMA) at various embryonic
tages. At embryonic day 11.5 postcoitum (E11.5), the aorta
s beginning to become invested by a single layer of smooth
uscle. At this stage, the endothelium of the aorta as well
s of its sprouts expresses high levels of ephrin-B2 (Figs.
A–3C). In contrast, the single layer of smooth-muscle cells
round the aorta lacks detectable ephrin-B2 expression (Fig.
C). However, it appears as if some mesenchymal cells
cattered around the aorta strongly express ephrin-B2 at this
tage (Fig. 3B). During the next few embryonic days, the
mooth muscle of the aorta gains many more layers of
mooth muscle, and these circumferential smooth muscle
ells strongly express ephrin-B2, as does the endothelium
Figs. 3D–3F); once again, more distantly surrounding cells
lso express ephrin-B2 (Fig. 3E), and it is unclear whether
hese ephrin-B2-expressing mesenchymal cells are precur-
ors that have given rise to, or will continue to give rise to,
he layers of smooth-muscle cells.
Copyright © 2001 by Academic Press. All rightWhile most major arteries expressed ephrin-B2 within
heir smooth-muscle cell layers at E14.5, there were notable
xceptions. For example, ephrin-B2 was highly expressed by
he endothelium, but not the surrounding smooth-muscle
ells, of the umbilical artery (Figs. 3G–3I).
Taken together, these results demonstrate that initially
he vascular endothelium is ephrin-B2 positive at develop-
ental stages when there is little or no surrounding
mooth-muscle layer. While the initial layer of smooth-
uscle cells appears not to express ephrin-B2, closely
urrounding mesenchymal cells do express it strongly.
hortly thereafter, arteries become invested in many layers
f smooth muscle, all of which strongly express ephrin-B2.
Ephrin-B2 Is Highly Expressed at Sites of
Secondary Angiogenesis in the Embryo, as Well as
at Sites of Normal and Pathological Angiogenesis
in the Adult
As in the adult, ephrin-B2 clearly marks the arterial
vascular tree at E14.5 (Fig. 4A). At this stage, numerous
initially avascular structures are being invaded by robust
secondary angiogenic processes. For example, at these
stages the formerly avascular heart becomes vascularized.
While the cardiac muscle cells do not express ephrin-B2, the
newly forming coronary arterioles strongly express
ephrin-B2 (Fig. 4B) within their endothelium as well as their
smooth muscle; similarly high ephrin-B2 expression marks
the arterial circulation at other sites of secondary angiogen-
esis in the embryo, such as in the developing neural tube,
kidney, and lung (not shown). In the heart, it should be
noted that ephrin-B2 is also highly expressed by the endo-
cardium, most notably overlying the newly formed atrio-
ventricular valves as well as the septa forming between the
right and left atrium (Fig. 4B, and data not shown).
Our observations of high levels of ephrin-B2 expression at
sites of secondary angiogenesis in embryos prompted us to
examine sites of physiologic as well as pathologic angiogen-
esis in the adult. Physiologic angiogenesis accompanies
follicular maturation and corpus luteum formation in the
adult ovary. During follicular maturation, the avascular
follicle becomes surrounded by new vessels permeating its
theca interna, and these vessels strongly express ephrin-B2
(Fig. 4C). After the mature follicle exudes its ovum, it
undergoes further differentiation to form a highly vascular-
ized corpus luteum, and the new vessels invading the
corpus luteum also express high levels of ephrin-B2 (Fig.
4D). In the angiogenic vessels surrounding the follicle or
invading the corpus luteum, ephrin-B2 appears to be ex-
pressed by the endothelium.
To examine the expression of ephrin-B2 during patho-
logic angiogenesis, subcutaneous tumors were examined. In
a dramatic example of one such tumor that had invaded the
underlying muscle, it can be seen that certain vessels
growing into the tumor from the surrounding muscle ex-
press high levels of ephrin-B2 (Fig. 4E). Consistent with the
notion that ephrin-B2 marks arterial and not venous ves-
s of reproduction in any form reserved.
157Ephrin-B2 Labels Arteries of Embryos and Adultssels, these tumor vessels appear to arise from previously
existing ephrin-B2-expressing arterioles within the
muscle (Fig. 4E). These data suggest that tumor vessels,
which were previously assumed to consist of homog-
enous capillaries based on their small size and paucity of
smooth-muscle investiture (e.g., Folkman, 1971), may be
divided into microvessels with either arterial or venous
identity. Further consistent with this notion, it is clear
that only a subset of the new tumor vessels are ephrin-B2
positive (Figs. 4F– 4H). Finally, ephrin-B2 was expressed
by the endothelium of tumor vessels (Figs. 4F and 4I);
smooth-muscle cells associated with tumor vessels
FIG. 3. During development, ephrin-B2 progressively extends fro
smooth muscle. (A–I) From ephrin-B2/LacZ embryos. (A–C) Sectio
and SMA localization, respectively, in E11.5 day mouse aorta reveal
around the aorta (closed arrowheads in A, and open arrowheads in
sprouts, have not yet become invested with smooth muscle cell
surrounding the aorta, and in C indicate ephrin-B2 negative SM
ephrin-B2/LacZ, and SMA localization in adjacent section of E14.5 d
and ephrin-B2 positive structures. (G–H) PECAM, ephrin-B2/Lac
umbilical arteries revealing a high degree of correspondence betwee
arteries. Arteries (A), veins (V), and gut (G) are indicated.clearly did not express ephrin-B2.
Copyright © 2001 by Academic Press. All rightDISCUSSION
The initial findings that ephrin-B2 marks the arterial
endothelium at the earliest stages of embryonic angiogen-
esis, and that its EphB4 receptor reciprocally marks the
venous endothelium, suggested that ephrin-B2 and EphB4
might be involved in the establishment of arterial versus
venous identity (Adams et al., 1999; Wang et al., 1998). A
puzzling aspect of these initial findings was that despite
their global distributions on their respective sides of the
vasculature, the ephrin-B2 ligand and its EphB4 receptor
only seemed to have the opportunity to engage each other at
pecifically marking arterial endothelium to also marking arterial
ere immunohistochemically labeled for PECAM, ephrin-B2/LacZ,
ephrin-B2 marks the endothelium and not the smooth-muscle cells
). Ephrin-B2 expressing endothelial cells, some of which exist as
osed arrows in B indicate ephrin-B2 positive mesenchymal cells
sitive smooth muscle cells investing the aorta. (D–F) PECAM,
ouse aorta, showing a high degree of correspondence between SMA
d SMA localization in adjacent sections from E14.5 day mouse
CAM and ephrin-B2 positive cells in the endothelium of umbilicalm s
ns w
that
B–C
s. Cl
A po
ay m
Z, an
n PEthe junctions of arterial and venous vessels. Indeed, this
s of reproduction in any form reserved.
158 Gale et al.FIG. 4. Ephrin-B2 is highly expressed at sites of secondary angiogenesis in the embryo, as well as at sites of normal and pathological
angiogenesis in the adult. (A–I) From ephrin-B2/LacZ mice. (A) Ephrin–LacZ expression in dorsal view of thoracic organs from E14.5 day
mouse reveals extensive expression in all arteries present but not in veins (not visible). Aorta (Ao), subclavian artery (sa), common carotid
arteries (cca), ductus arteriosus (da), pulmonary arteries (pa), esophagus (Eo), and bronchial epithelium (Br) are indicated. (B) Section of E14.5
day heart reacted for b-Gal revealed high levels of expression of ephrin-B2/LacZ in new coronary vessels of the ventricular wall and septum.
Expression was also observed in developing atrial septa and within the endocardium over the trabeculae and atrioventricular valves
Copyright © 2001 by Academic Press. All rights of reproduction in any form reserved.
159Ephrin-B2 Labels Arteries of Embryos and Adultspossibility led to the speculation that ephrin-B2 and EphB4
might actually be involved in regulating the proper forma-
tion of such anastomoses and in preventing inappropriate
fusions between tangential aspects of arterial and venous
vessels (Adams et al., 1999; Wang et al., 1998; Yancopoulos
et al., 1998). Unfortunately, the early death of embryos
lacking ephrin-B2 or EphB4 did not allow for analysis of the
ongoing roles of this requisite ligand–receptor pair in vivo.
Our current findings suggest a much more extensive and
ongoing role for EphB4 and ephrin-B2 in arterial vessels. We
have found that ephrin-B2 expression continues to selec-
tively mark arteries during later embryonic development,
as well as in the adult. Furthermore, as development
proceeds, we find that ephrin-B2 expression progressively
extends from the arterial endothelium to surrounding arte-
rial smooth-muscle cells and to pericytes. That is,
ephrin-B2 is initially expressed by the vascular endothe-
lium of primary vessels and their sprouts, and not by the
first layer of smooth-muscle cells that begin to invest the
vasculature. Soon thereafter, the multiple layers of smooth-
muscle cells enveloping arterial vessels begin to highly
express ephrin-B2, as do loosely associated mesenchymal
cells, which may be smooth-muscle precursors surrounding
these vessels; ephrin-B2 remains highly expressed in the
endothelium and smooth muscle of adult arterial vessels.
Altogether, these findings suggest that ephrin-B2 might be
involved, in an ongoing fashion, in regulating endothelial–
smooth-muscle interactions involved in the formation and
maintenance of the muscular walls of arteries. Further-
more, coexpression of EphB4 with ephrin-B2 in the aorta
(data not shown and Shin et al., 2000) suggests that ligand–
receptor pair can act together within the arterial vessel wall
and that interaction of ephrin-B2 and EphB4 is thus not
strictly limited to mediating interactions between arterial
and venous compartments; additional EphB receptors may
be involved.
Just as the detailed architecture and properties of the
vasculature differ in different tissues, the precise distribu-
tion of ephrin-B2 differs in different vascular beds, as does
the relative expression levels of ephrin-B2 by endothelium
as opposed to smooth muscle in these vascular beds. Also
variable is the precise point, between the arterial and
venous circulation, at which ephrin-B2 expression becomes
undetectable. In some cases, such as in the microvascula-
ture of particular muscles and in the trachea, we were able
to show that the endothelium and pericytes of capillaries
(arrowheads) as indicated. (C–D) Ephrin-B2/LacZ is strongly expre
indicate capillaries in the neovasculature (arrowheads) of the corpu
in the neovasculature of a subcutaneously grown tumor (Lewis Lu
(indicated by closed arrowheads), but is found in longitudinally orien
view (inset). (G–I) Ephrin-B2 expression in a subset of tumor endot
of the endothelial cells labeled by PECAM (H). Corresponding regi
tumor dual-labeled for beta-galactosidase and smooth muscle a
arrowheads), but not in pericytes (red arrowheads).
Copyright © 2001 by Academic Press. All rightstill express ephrin-B2, with expression becoming undetect-
able midway between terminal arterioles and postcapillary
venules. These findings suggest that capillaries can be
divided into an arterial subset that maintains arterial iden-
tity and a venous subset that maintains venous identity,
contrary to earlier views that capillaries lack arterial/
venous distinctions.
In adult settings of physiologic and pathologic angiogen-
esis during remodeling of the female reproductive system or
in tumors, ephrin-B2 seems to recapitulate its earliest
patterns of embryonic expression. That is, ephrin-B2 is
highly expressed by the endothelium of some angiogenic
vessels and their sprouts and is largely lacking from the few
smooth-muscle cells that are associated with new vessels.
The finding that angiogenic sprouts at sites of adult neo-
vascularization have arterial identity challenges prevailing
views that these sprouts largely derive from postcapillary
venules and lack arterial identity (Gimbrone et al., 1974;
Grunt et al., 1986a,1986b). Instead, our data suggest that
adult angiogenic signals cause recapitulation of an embry-
onic process in which ephrin-B2 might initially be involved
in arterial sprouting and perhaps in anastomoses with
EphB4-expressing venous sprouts, followed by playing a
role in maturation of the arterial vessels by regulating
formation of the muscle wall.
Whatever the roles of ephrin-B2 during arterial sprouting
and wall formation, any such roles seem likely to depend on
interactions of ephrin-B2 with its cognate EphB receptors.
As noted above, such interactions would presumably de-
pend on cell-to-cell contact between cells bearing the
membrane-tethered ephrin-B2 and its EphB receptors and
could result in bidirectional signaling between these adja-
cent cells. Though initial work had focused on the recipro-
cal distribution of the EphB4 receptor in the venous circu-
lation of the embryo (Gerety et al., 1999; Wang et al., 1998),
more recent findings indicate that several EphB receptors
are more widely expressed so as to have direct access to
arterial ephrin-B2 (Adams et al., 1999) and this study;
consistent with the notion that EphB2 and EphB3 receptors
play normal roles during vascular development, double null
mutants for EphB2/EphB3 receptors display vascular de-
fects. Furthermore, the finding that EphB4 is expressed in
the aorta (data not shown and Shin et al., 2000) indicate that
it too might have direct access to ephrin-B2 within arterial
muscle walls.
Some of the findings in this manuscript are corroborated
during physiological maturation of ovarian follicles. (C) Arrows
um after ovulation (D). (E–F) Ephrin-B2/LacZ is strongly expressed
rcinoma). At high magnification LacZ staining is absent in veins
ndothelial cells (open arrowheads in F), also seen in a higher power
l cells. (G) Beta-galactosidase immunostaining marks a proportion
etween G and H indicated by white arrowheads. (I) In a section of
(SMA), ephrin-B2 activity is found in endothelial cells (greenssed
s lute
ng ca
ted e
helia
ons b
ctins of reproduction in any form reserved.
B160 Gale et al.in the simultaneous submission by Shin et al. (2000).
Earlier studies had focused on a role for ephrin-B2 during
the earliest embryonic stages of arterial/venous determina-
tion. Our current findings together with those of Shin et al.,
using ephrin-B2 as an arterial marker in the adult, challenge
prevailing views of the arterial/venous identity of quiescent
as well as remodeling adult microvessels. In addition, our
findings also highlight a possible role for ephrin-B2 in the
formation of the arterial muscle wall, perhaps by regulating
endothelial–smooth-muscle interactions involved in the
formation of the muscle wall. Further meaningful insight
into the role of ephrin-B2 during arterial development will
presumably depend on examining the requirement for
ephrin-B2 in vivo. The early death of mouse embryos
lacking ephrin-B2, and the poorly defined vascular defects
in these embryos, has limited their usefulness for this
purpose. It seems likely that further understanding the role
of ephrin-B2 during later arterial vessel development, and
the purpose behind its fascinating expression patterns, will
depend on genetic manipulation of the ephrin-B2 system in
a regulated fashion during later stages of embryonic devel-
opment as well as in the adult.
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